MICROSCOPIC POLYANGIITIS
Clinical trials for MICROSCOPIC POLYANGIITIS explained in plain language.
Never miss a new study
Get alerted when new MICROSCOPIC POLYANGIITIS trials appear
Sign up with your email to follow new studies for MICROSCOPIC POLYANGIITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug tested for rare vasculitis falls short
Disease control TerminatedThis study tested whether a newer drug, obinutuzumab, works better than the standard drug rituximab for a rare disease that causes inflammation of blood vessels (ANCA-associated vasculitis). The goal was to see if patients could achieve remission and clear certain antibodies from…
Matched conditions: MICROSCOPIC POLYANGIITIS
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Hydroxychloroquine trial for rare vasculitis halted early
Disease control TerminatedThis study tested whether adding hydroxychloroquine to standard treatment could better control ANCA vasculitis, a group of autoimmune diseases that cause inflammation of blood vessels. It enrolled 43 adults with mild disease activity. The trial was terminated early, so results ar…
Matched conditions: MICROSCOPIC POLYANGIITIS
Phase: PHASE4 • Sponsor: Guy's and St Thomas' NHS Foundation Trust • Aim: Disease control
Last updated May 13, 2026 16:01 UTC